syh2051
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 15, 2023 (NCT06011291)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Serine-protein kinase ATMINHIBITOR
ATM inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06775236 | Phase 1/Phase 2 (Phase 2) | Mar 20, 2025 | Shijiazhuang Pharma Group (CSPC) |
| NCT07104877 | N/A | Apr 18, 2024 | Fujian Medical University |
| NCT06011291 | Phase 1 | Aug 15, 2023 | Shijiazhuang Pharma Group (CSPC) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shijiazhuang Pharma Group (CSPC) | For profit | 2 | 2 | 2 | 2023 |
| Fujian Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1